Last quarter (Q0 0), Altamira Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q0, Altamira Therapeutics's net income was $―. See Altamira Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ 27.29K	$ 305.62K	$ 63.88K	$ 0.00	$ 0.00
Cost of Revenue	$ ―	$ ―	$ 1.44M	$ 2.24M	$ 0.00	$ ―
Gross Profit	$ ―	$ 27.29K	$ -1.14M	$ -2.18M	$ 0.00	$ ―
Operating Expense	$ ―	$ 6.17M	$ 25.70M	$ 14.81M	$ 5.28M	$ 7.26M
Operating Income	$ ―	$ -6.14M	$ -26.84M	$ -16.98M	$ -5.28M	$ -7.26M
Net Non Operating Interest Income Expense	$ ―	$ -1.31M	$ -911.87K	$ -189.69K	$ -134.89K	$ -10.75K
Other Income Expense	$ ―	$ -188.75K	$ -1.66M	$ -69.06K	$ -2.80M	$ 444.15K
Pretax Income	$ ―	$ -7.27M	$ -26.04M	$ -16.77M	$ -8.22M	$ -6.83M
Tax Provision	$ ―	$ ―	$ -10.33K	$ 21.62K	$ -21.28K	$ -193.84K
Earnings From Equity Interest Net Of Tax	$ ―	$ -39.56K	$ 709.45K	$ 264.98K	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -3.87M	$ -26.03M	$ -16.80M	$ -8.20M	$ -6.63M
Basic EPS	$ ―	$ ―	$ -29.13	$ ―	$ -1.36	$ -2.28
Diluted EPS	$ ―	$ ―	$ -29.13	$ ―	$ -1.36	$ -2.28
Basic Average Shares	$ ―	$ ―	$ 910.72K	$ 13.25M	$ 6.01M	$ 2.91M
Diluted Average Shares	$ ―	$ ―	$ 893.48K	$ ―	$ 6.01M	$ 2.91M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ 13.87K	$ 27.36K
Total Expenses	$ ―	$ 6.17M	$ 27.15M	$ 17.05M	$ 5.28M	$ 7.26M
Net Income From Continuing And Discontinued Operation	$ ―	$ -3.87M	$ -26.03M	$ -16.80M	$ -8.20M	$ -6.63M
Normalized Income	$ ―	$ -5.34M	$ ―	$ ―	$ -5.40M	$ -7.06M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ 135.15K	$ 28.63K
EBIT	$ ―	$ -5.60M	$ -25.13M	$ -16.58M	$ -8.09M	$ -6.80M
EBITDA	$ ―	$ -5.48M	$ -25.01M	$ -16.51M	$ -8.07M	$ -6.77M

Currency in USD

Altamira Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing